

Index

- AAV2-neurturin, 273, 276
acamprostate, 17
acceptability, rating scales, 232
accordion-pill carbidopa-levodopa, 86
acetylcholine deficiency, 141
activities of daily living (ADLs), 122, 199, 351
acupuncture, 353
acute anticholinergic syndrome, 10
ADAGIO study, 26, 30, 269, 272, 274, 275, 328
ADAS-cog scale, 325, 326, 332
ADCS-CGIC scale, 325, 332
adenosine A2a antagonists, 86
 istradefylline, 86–87
 preladenant, 87
 tozadenant, 87–88
ADS-5102, 89
advanced stage PD
 COMT inhibitors, 78, 80
 DBS, 313–16
 levodopa treatment summary, 72–73
adverse effects
 anticholinergics, 9–10
 apomorphine, 57
 bilateral pallidal DBS, 304
 bilateral pallidotomy, 303
 DBS, 314, 317
 donepezil, 326
 dopamine agonists, 41–43
 intranasal apomorphine, 53
 rasagiline, 27
 rivastigmine, 326
 rotigotine transdermal system, 52
 selegiline, 27
 STN DBS, 198, 199–202, 306
 subthalamotomy, 305
 surgery, 308
 thalamotomy vs thalamic DBS, 299
 tolcapone, 79
 VIM DBS, 211, 212
AE program, 285
aerobic exercise, 349–50
AFQ056, 89–90
agoraphobia, 130
AIMS scale, 233
akathisia, 165, 166
akinetic crisis, 16
akinetic rigid syndromes, 2
ALDS scale, 304, 307
alertness, 151, 218
alpha-blockers, 103
alpha-synuclein, 253–54, 268
Alzheimer's disease, 76, 111, 117, 125, 128, 141
 beta-amyloid and tau proteins, 255
AM IMPAKT study, 56
amantadine, 13–20, 101
 ADS-5102, 89
 compulsive behaviour treatment, 17
 dyskinesias treatment, 14
 ICDs, 329
 levodopa and, 69
amitriptyline, 101
amnesic multiple-domain MCI, 122
amnesic single-domain MCI, 111, 122
amphetamine, 135
amyloid, beta, 255, 268
analgesics, 165, 167
anger, 291
animal models, 270–71
 dopaminergic neuroprotection, 318
 exercise, 350
 lack of, 266
 toxin-induced, 271
 transgenic, 271
antibodies measured, 257
anticholinergics, 5–10, 132
 adverse effects and contraindications, 9–10
 current use in PD management, 7–9
 future use, 10
 levodopa synergy, 9
 pharmacokinetics and pharmacodynamics, 6–7
 psychosis effects, 141
 sialorrhea, 101
 urinary dysfunction, 102
antidepressants, 27, 104, 112, 130, 133, 167
 tricyclic, 103, 133, 327
antidyskinetics, 89–90
antiglutamatergics, 13–20
 akinetic crisis and neuroleptic malignant syndrome, 16
 cognitive improvement, 16
 dyskinesia studies, 16
 evidence-based results and meta analyses, 14–16
 four main effects, 18
 ICD and other compulsive disorders, 17–18
 psychosis induction, 17
antihypertensives, 104
antimuscarinics, 5
antipsychotics, 132, 141
anxiety, 128, 129–31, 330
 categories, 130
apathy, 128–29, 330
 DBS and, 147
 definitions, 128
 depression and dementia, 129
 syndrome, 129
 treatment, 129
apomorphine, 53–54, 80, 155
 adverse effects, 57
 ICDs, 57
 intranasal, 53
 long-term therapy effects, 57
 motor effects, 54–56
 non-motor effects, 56–57
 pain relief, 166
 pharmacokinetics, 54
 sexual dysfunction, 104
 subcutaneous, 100
 transdermal patch, 52
aripiprazole, 132, 329
art therapy, 356
aspiration pneumonia, 340
ataxia, limb, 183
atomoxetine, 124, 326
atropine, 5, 101
attention deficit disorder, 326
attention training, 113
atypical parkinsonism, 66, 196, 243, 281
auditory cues, 354
auditory hallucinations, 131
autonomic dysfunction, 93. *See also*
 constipation; gastroparesis;
 orthostatic hypotension; sialorrhea
 defecatory, 100
 drug treatment, 95
 sexual, 104–6
 thermoregulatory, 106
 urinary, 102–4
axial symptoms, anticholinergic effects on, 8
back pain, 166
bapineuzemab, 255
Barthel index, 300
Beck Depression Inventory (BDI), 291
behavioral disturbances, 127. *See also*
 depression; fatigue; impulse control disorders (ICD); psychosis
 anxiety, 128, 129–31, 330
 apathy, 128–29, 330
 deep brain stimulation and, 146–48
 drug treatment, 148
 personality, 128
 treatment-related, 139–40

Index

- behavioral treatment, urinary dysfunction, 102, 343
- benign prostatic hypertrophy, 103
- benign tremulous parkinsonism, 213
- benserazide, 23, 67, 76
- benzodiazepines, 130
- benztropine, 7
- beta-amyloid, 255, 268
- bilateral GPi DBS, 303–4
- bilateral pallidotomy, 302
- bilateral posteroventral pallidotomy, 302
- bilateral subthalamic DBS, 306–8
- bilateral subthalamotomy, 306
- bilateral thalamotomy, 179, 299, 300
- biofeedback, 100
- BioFIND study, 251
- biomarkers, 268
- CSF and blood, 250–53
 - definition, 249
 - dopamine-based, 253–58
 - future directions, 259–60
 - ideal characteristics for PD, 251
 - in clinical trials, 250
 - metabolomics, 259
 - neuroimaging, 250, 267
 - neuroprotective trials, 266, 268
 - proteomics, 259
 - transcriptomics, 258–59
- biperiden, 7
- bisacodyl, 99
- blood biomarkers, 250–53
- dopamine-based, 253–58
- Botox, 100, 103, 338
- botulinum toxin, 93, 95, 98, 100, 101, 103
- botulinum toxin type A, 337–39
- urinary dysfunction, 342
- botulinum toxin type B, 339
- bradykinesia, 2, 289
- brain function, measurement in trials, 246
- brain network imaging, 243
- bromocriptine, 34, 35
- bupropion, 133, 327
- cabergoline, 35, 37, 155, 156
- caffeine, 157, 345
- calcium channel antagonists, 90
- CALM-PD study, 38, 244, 250, 267, 272, 275
- CAPIT protocol, 195
- CAPSIT protocol, 177, 195–96, 197
- car accidents, 41, 152, 154
- carbidopa, 23, 67, 68, 69, 70, 76
- accordion pill, 86
 - intestinal gel, 70–71, 83–84
- cardiac pacing, 97
- Carlsson, Arvid, 1
- carpal tunnel syndrome, 166
- catechol-o-methyl transferase (COMT) inhibitors, 67–68, 76–81
- catheterization, 103
- CATIE-AD trial, 333
- caudal Zona incerta (cZi), 218
- central fatigue, 134
- central pain, 165, 167
- centromedian-parafascicular complex (CM-Pf), 221
- CEP-1347, 273, 276
- cerebellothalamic tract, 219
- cerebrospinal fluid (CSF) biomarkers, 250–53
- dopamine-based, 253–58
- CGI scale, 344
- Charcot, Professor, 5
- Charles Bonnet's syndrome, 141
- chewing gum, 101
- cholinergic system, 5–6
- cholinesterase inhibitors, 112, 123–24, 129, 132, 141
- CIBIC scale, 326
- cisapride, 98, 99
- CISI-PD scale, 233
- citalopram, 328
- classical test theory (CTT), 231
- CLEOPATRA-PD study, 40
- clinical trials. *See also* neuroprotective trials
- biomarkers in, 250
 - design, 270–71
 - early stage PD, 280–85
 - functional imaging markers in, 244–46
 - NPS, 330–33
- clinician-based rating scales, 232–34
- clonazepam, 156
- closed-loop devices, 224
- clozapine, 132, 141, 329
- Cochrane review
- anticholinergics, 8
 - monoamine oxidase inhibitors, 25
- coenzyme Q10, 256, 273, 277
- cog wheeling, 3
- cognitive behavioral therapy (CBT), 134, 328
- cognitive impairment, 293. *See also* mild cognitive impairment (MCI)
- background, 111–12
 - drug treatment, 112, 123–24, 124
 - epidemiology, 122
 - exercise and, 350
 - future directions, 118
 - GPi DBS, 191
 - GPi vs STN DBS, 290
 - neuropsychological profile and bedside assessment, 122–23
 - non-drug interventions, 116–18, 125
- cognitive improvement, 16, 352
- cognitive rehabilitation, 113, 116–17
- cognitive stimulation, 114, 117
- colchicine, 100
- COMPARE study, 342
- COMPASS-OD scale, 344
- compensatory rehabilitation, 112, 117
- composite endpoints, 332
- compulsive disorders, 17–18
- COMT inhibitors. *See* catechol-o-methyl transferase (COMT) inhibitors
- consistency, rating scales, 232
- constant voltage stimulator, 225
- constipation, 98–100, 341–42
- drug treatment, 95
- continuous drug delivery (CDD), 48
- controlled release levodopa, 67
- Cotzias, George, 1
- cranial electrotherapy stimulation (CES), 168
- creatine, 272, 276
- creative arts therapies, 353–57
- CSP 468 study, 190
- CVT-301, 86
- cyclic GMP phosphodiesterase type 5 inhibitors, 105
- cystometric analysis, 342
- DAICE-ET survey, 52
- Dai-Kenchu-To (DKT), 100
- dance therapy, 355–56
- darifenacin, 103
- DAT scans, 267, 281
- DATATOP study, 24, 27, 90, 251, 254, 255, 271, 272
- DAWS (DAg withdrawal syndrome), 43, 144–45
- daytime sleep disorders, 41, 152–53, 345–46
- deep brain stimulation (DBS), 83, 118, 146–48, 157–58. *See also* globus pallidus internus (GPi) DBS; subthalamic nucleus (STN) DBS; ventral intermediate nucleus (VIM) DBS
- advanced stage PD, 313–16
 - advantages and drawbacks, 298
 - alternative targets, 202
 - awake/asleep, 292
 - centromedian-parafascicular complex, 221
 - development, 176
 - early stage PD, 282–83, 320–22
 - hemorrhage risk, 182
 - introduction, 297
 - mid stage PD, 316–20
 - novel stimulation paradigms and devices, 224–25
 - nucleus basalis of Meynert, 221–22
 - other targets, 216
 - pain relief, 162, 166, 167
 - pedunculopontine nucleus, 216–18, 218
 - posterior subthalamic area, 218–19
 - post-operative surveillance, 147
 - substantia nigra, 219–21
 - vs. surgery controversy, 308–9
 - thalamic, 298–300
- defecatory dysfunction, 100
- delayed-start design, 265, 269–70, 274
- delirium, 141
- delusions, 131, 135, 140
- dementia, 111, 112, 122, 128, 135, 325–27. *See also* Alzheimer's disease
- DBS and, 196
 - depression and apathy, 129
 - with Lewy bodies, 128, 131
 - NBM DBS and, 222
 - psychosis and, 131
- Denny-Brown, Derek, 1
- depression, 132–34, 327–28
- anxiety and, 130
 - apathy and dementia, 129
 - categories, 128
 - DBS and, 147, 196
 - fatigue and, 127
 - GPi vs STN DBS, 291
 - pain and, 164, 167

- pramipexole effects on, 39
treatment, 133–34
- desmopressin, 97, 103
- despiramine, 328
- detrusor areflexia, 103
- dextromethorphan, 16
- DFSS scale, 339
- Diagnostic and Statistical Manual (DSM)
IV TR, 127, 128, 130, 132, 332
- Diagnostic and Statistical Manual (DSM)
V TR, 142
- diet, 97
high-fiber, 98
- disease modification, 265
- disease-modifying treatments, 90
- DJ-1 gene, 254
- DM-1992, 86
- docusate, 99
- domperidone, 54, 57, 93, 95, 96, 97, 344
- donepezil, 123, 124, 331
cognitive impairment, 112, 113, 326
- DOPA decarboxylases, inhibitors, 63, 66
- dopamine
based biomarkers, 253–58
compulsive misuse, 147
- dopamine agonist withdrawal syndrome
(DAWS), 43, 144–45
- dopamine agonists, 34–35
adverse effects, 41–43
continuous drug delivery, 48
early stage PD, 283–85
ICDs and, 142, 143
intranasal, 53
levodopa and, 69
major clinical trials, 275
most common daily usage, 37–41
pharmacodynamics, 36–37
pharmacokinetics, 37
rationale for use in PD, 35–36
sexual dysfunction, 104
subcutaneous, 53–58
transdermal, 48–53, 58
- dopamine dysregulation syndrome, 66,
142, 143–44
- dopamine receptors, classes, 36
- dopamine system
functional imaging, 242–44
integrity, 245
- dopaminergic areas of the brain, 153
- dopaminergic neuroimaging, 266–67
- dopaminergic neuroprotection, 319
- doxepin, 156
- drooling, 100. *See also* sialorrhea
- droxidopa, 94, 95, 96
- duloxetine, 167, 344
- duodenal delivery methods, 70
- dysarthria, 211
- dysautonomia scale, 236
- dyskinesias. *See also* motor symptoms
amantadine effects on, 14
antidyskinetics, 89–90
antiglutamatergic studies, 16
DBS, 190
development in PD, 13
GPi vs STN DBS, 289
levodopa-induced, 13, 65, 89, 289
- pallidotomy effect on, 179
rating scales, 233
STN DBS and, 199
thalamotomy effect on, 178
- dysphagia, 340–41
- Dysport, 101, 104, 337, 342
- dystonia
anticholinergic effects on, 8
pain related to, 165–66
- early stage PD
clinical trials, 280–85
DBS, 282–83, 320–22
definition, 280
exercise, 285
medications, 283–85
MRI scanning, 281
nuclear imaging, 281–82
severity and onset of symptoms, 280
somatostatin levels, 282
treatment summary, 72
vitamin D deficiency, 282
- EARLYSTIM trial, 196
- economic impact, 315, 318
- edemas, pedal and peripheral, 42
- effect size (ES), 231
- EFNS classification, 23, 28, 30
- elderly
anticholinergic adverse effects, 9
summary of treatments in early stage
PD, 72
- electrical stimulation, 342
cranial electrotherapy, 168
gastric, 98
surface therapy, 341
tDCS, 118
- electroconvulsive therapy (ECT), 133, 135, 224
- ELLDOPA study, 65, 134, 250, 267, 272, 274
- emotional incontinence, 135
- EMST device, 340
- entacapone, 67, 68, 77, 78–79
- epidural spinal cord stimulation (eSCS),
222–24
- Epworth sleepiness scale, 153, 154, 345
- EQ-5D scale, 237
- erectile dysfunction, 104–5, 343
drug treatment, 95
- erythromycin, 98
- erythropoietin, 97
- eszopiclone, 155, 346
- excessive daytime sleepiness (EDS), 152,
157, 345
- excitotoxicity, 123
- executive dysfunction, 111, 122
- exercise. *See* physical exercise
- external cues, 354
- fatigue, 134–35
depression and, 127
scales, 236
- Fatigue Assessment inventory, 134
- FBF program, 285
- FD-PET, 266
- feasibility, rating scales, 232
- fiberoptic endoscopy, 340
- fibrosis, 69
- FILOMEN study, 78
- fipamezole, 89
- Fitness Counts* program, 285
- fludrocortisone, 94, 95, 344
- fluorodopa PET (Fdopa PET), 316
- fMRI scanning, 243
- forced aerobic exercise, 350
- freezing of gait, 221
scale (FOGQ), 235
- Frenchay Activities Index, 179, 299
- FSS scale, 236
- functional imaging, 242
dopamine system integrity, 242–44
functional imaging markers, 244
in clinical trials, 244–46
outcome measures development, 246–47
futility studies, 270
- gait abnormalities, 3, 221, 289
- gait improvement, 351, 354
- gait training, 350, 354
- galantamine, 123, 124
- gambling, pathological, 142
- gastric electrical stimulation, 98
- gastrointestinal symptoms scale, 236
- gastroparesis, 56, 97–98
drug treatment, 95
- gel electrophoresis, 2D, 259
- generalized anxiety, 130
- Global Biomarkers Standardization
Consortium (GBSC), 260
- globus pallidus externus (GPE), 288
- globus pallidus internus (GPi) DBS, 146,
147, 187, 287
anatomy and physiology, 287–88
background, 287
bilateral, 303–4
complications, 190–92
mechanism, 187–88
medication reduction, 292
motor symptoms, 289–90
neuroimaging, 292
non-motor symptoms, 290–91
operation risks, 293
outcomes, 189
patient selection, 188
programming challenges following, 292
stimulation, 288
vs. STN DBS, 190, 192, 294
technique, 188–89
unilateral, 301–2
- glucose metabolism, 267
- glutamate receptors, 15, 16
- glutamatergic neurotransmission, 13, 14
- glutathione, 256
- glycopyrrolate, 93, 95, 101, 340
- group singing, 354
- hallucinations, 131, 140, 141
auditory, 131
minor, 140
presence and passage, 131
visual, 131, 141
- HDRS-17 scores, 327
- health-related quality of life scales, 236–37,
238

Index

- hedonistic homeostatic dysregulation, 144
hemiballism, 182, 183
hemorrhage, 182, 293
 intracranial, 201
hepatotoxicity, 79
Hoehn and Yahr staging (HY), 4, 232, 280
homovanillic acid (HVA), 253
Hopkins verbal learning test, 290
5HT_{2A}, 141
5HT₄ agonists, 99
Human Plasma Proteome Project (HPPP), 260
hypersexuality, 104, 142
hypomania, 142, 147
hypotension. *See also* orthostatic hypotension
 postural, 42, 105
- illusions, 140
immunotherapy, 254
impulse control disorders (ICD), 13, 17–18, 329
 apomorphine and, 57
 characterization, 142
 dopamine agonists, 35, 42
 rotigotine role in, 52
 scales, 236
 treatment related, 142–43
incontinence
 urge incontinence, 102
 urinary, 343
indomethacin, 97, 343
inflammation markers, 256–58
infusion levodopa therapy, 70–72
inosine, 90, 256, 257
insomnia, 151, 155–56
interpretability, in rating scales, 231
intranasal dopamine agonists, 53
ionotropic glutamates, 15, 16
ipratropium bromide, 101, 339
IPX066, 69, 84–85
ischemic stroke, 201
isradipine, 90, 284
istradefylline, 86–87
item response theory (IRT), 231
iTRAQ analysis, 259
- Lactobacillus casei* Shirota, 99
lactulose, 99
L-amino acid decarboxylase (L-AAD), 76, 81
LARGO study, 26, 80
latent trait theories (LTT), 231
lateral pain system, 162
laxatives, 99
lazabemide, 25
L-deprenyl. *See* selegiline
LEAPS study, 275
lesioning, 178. *See also* surgery
 size of lesion, 308
levodopa, 63, 76. *See also* carbidopa
 advanced-stage PD treatment summary, 72–73
 amantadine and, 69
 anticholinergic synergy, 9
 COMT inhibitors and, 67–68
 controlled release, 67
 dopamine agonists and, 69
 early-stage PD treatment summary, 72
 history of PD therapy, 63–64
 infusion therapy, 70–72
 insomnia and, 155
 major trials, 272, 274–75
 monoamine oxidase inhibitors and, 68
 motor complications, 34, 35, 65
 non-motor complications, 65–66
 novel approaches to delivery, 83–86
 novel formulations, 69–70
 pain management, 344
 peripheral neuropathy and, 168, 169
 pharmacokinetics and
 pharmacodynamics, 64–65, 67, 68
 radiolabeled, 242
 rasagiline adjunct therapy, 25–26
 sleep disorders and, 156
 standard oral therapy, 66–67
levodopa induced dyskinesias (LIDs), 13, 65, 89, 289
levodopa test, 67
Levodopa-Carbidopa Intestinal Gel (LCIG), 70–71, 83–84
Lewy bodies, 253
 dementia with, 128, 131
Lewy, Freidrich, 1
limb ataxia, 183
liquid paraffin, 99
lisuride, 52, 58
local field potential (LFP) recording, 177
long-duration response, 64
lubiprostone, 93, 100, 342
- macroelectrode mapping, 177, 188, 189, 198
macrogol, 93, 99, 341
magnetic stimulation, 100
MALDI-TOF MS, 259
malondialdehyde, 256
mania, 142, 147
MAO inhibitors. *See* monoamine oxidase inhibitors
massage therapy, 353
Mattis Dementia Scale, 290
MCI. *See* mild cognitive impairment (MCI)
MDS-UPDRS, 233, 266
 M-EDL, 235
 nM-EDL, 235
medial pain system, 162
M-EDL scale, 235
melatonin, 155, 156, 346
memantine, 16, 17, 123, 346
 clinical trial, 331
 cognitive impairment, 113, 326
memory performance, 111
messenger RNAs (mRNAs), 258
metabolomics, 259
metabotropic glutamates, 15, 16
methylphenidate, 135, 157
metoclopramide, 98
MFI scale, 236
microelectrode mapping, 177, 188, 189, 198
microelectrode recording (MER), 287, 288, 292
microglial activation, 256
mid stage PD, DBS, 316–20
midodrine, 94, 95, 96
mild cognitive impairment (MC)
 types, 122
mild cognitive impairment (MCI), 111, 122, 325–27. *See also* cognitive impairment
 types, 111
minimally important change (MIC), 231, 232
minimally important difference (MID), 232, 233
minocycline, 272, 276
minor hallucinations, 140
mirabegron, 103
mirtazepine, 133
MitoQ study, 273
mitoquinone, 273
modafinil, 135, 157, 345
monoamine oxidase inhibitors, 23.
 See also rasigiline; selegiline
 background, 23
 COMT inhibitors and, 81
 future role, 28
 levodopa and, 68
 major trials, 271–74
 serotonin syndrome, 27–28
MONOCOMB study, 25
Montreal Cognitive Assessment (MoCA), 123
mosapride, 98, 99
motor changing rate (MCR), 52
motor complications and dyskinesia scales, 233
motor cortex stimulation (MCS), 222
motor impairment and disability scales, 233
motor symptoms. *See also* dyskinesias
 apomorphine effects on, 54–56
 drug treatment, 124
 GPI DBS vs. STN DBS, 289–90
 levodopa and, 34, 35, 65
 post-surgery, 183
 prevention of, 35
 rating scales, 233, 235
 ropinorole and, 39
 rotigotine and, 40, 50
 Tai-Chi and, 352
movement disorders
 categories, 2
 first recognition, 1
 improving, 353
Movement Disorders Society (MDS)
 definitions, 23, 29
 guidelines, 30
MPTP model, 271
MRI scanning, 243, 281
 fMRI, 243
multidomain scales, 233, 238
multimodal imaging, 244, 247
multiple domain MCI, 111, 122
multiple-system atrophy (MSA), 282, 343
muscle strength, loss of, 351
musculoskeletal pain, 164, 165
music therapy, 353–55

- naltrexone, 330
 ND0611, 70
 nebicapone, 77, 80
 Neria line, 54, 57
 NET-PD LS-1 study, 272
 NET-PD study, 272, 275
 neural stimulation, 115, 118
 neurodegeneration, measurement in trials, 245
 neuroimaging. *See also* PET scanning
 biomarkers, 250, 267
 dopaminergic, 266–67
 GPi DBS vs STN DBS, 292
 neuroinflammation, 243
 neuroleptic malignant syndrome, 16
 neuroleptics, 112
 neuromodulation, 104
 neuromuscular complications, 168–69
 neuropathic pain, 164, 165, 166
 neuroprotection, 265, 316, 320
 dopaminergic, 319
 neuroprotective trials. *See also* clinical trials
 animal models, 270–71
 biomarkers, 266, 268
 clinical measures, 266
 dopaminergic neuroimaging, 266–67
 future directions, 277
 glucose metabolism, 267
 limitations, 265–66
 results from major studies, 271, 272, 273, 271–77
 structural imaging, 268
 neuropsychiatric symptoms (NPS), 325.
 See also non-motor symptoms
 clinical trials, 330–33
 scales, 235
 neuropsychological tests, 116
 neurturin, 273, 276
 neutrophin-3, 100
 NHP scale, 237
 NICE guidelines, 25, 35
 nighttime sleep disorders, 151–52
 NMDA receptor antagonists, 112
 NMDA receptors, 123
 nM-EDL, 235
 NMS Questionnaire, 235
 nociceptive pain, 164
 nocturia, 102
 NOMESAFE study, 78
 non-amnesic multiple-domain MCI, 122
 non-amnesic single-domain MCI, 111, 122
 non-invasive brain stimulation, 224
 non-motor off symptoms, 127, 130
 non-motor symptoms, 337. *See also*
 autonomic dysfunction; behavioral
 disturbances; cognitive impairment;
 neuropsychiatric symptoms (NPS);
 sleep disorders
 apomorphine and, 56–57
 GPi vs STN DBS, 290–91
 levodopa, 65–66
 post-surgery, 183
 rating scales, 238
 ropinirole and, 39
 rotigotine and, 40
 rotigotine RTS and, 51
 scales, 234, 235–36
 therapeutic approach, 338
 Non-Motor Symptoms Scale (NMSS), 40,
 51, 55, 234
 nortriptyline, 327
 NPS. *See* neuropsychiatric symptoms (NPS)
 NSAIDs, 165
 nuclear imaging, 281–82
 nucleus basalis of Meynert (NBM), 221–22
 obstructive sleep apnoea (OSA), 152, 157
 octreotide, 97
 off phase, 65, 166, 179, 195
 6-OHDA model, 271, 319, 350
 olanzapine, 132, 329
 on phase, 65
 opicapone, 68, 77, 80
 optic tract, 188
 orthostatic hypotension, 42, 93–94, 343–44
 definition, 93
 drug treatment, 95, 94–97
 drugs causing, 94
 non-pharmacological management, 94
 symptoms, 93
 osmotic laxatives, 99
 outcome measures. *See also* clinical trials;
 rating scales
 functional imaging markers, challenges,
 245–46
 functional imaging markers,
 development, 246–47
 oxidative stress, markers, 255–56
 oxybutynin, 102
 pain, 162–68, 169–70, 344–45
 classification and treatment, 164, 165
 epidural spinal cord stimulation, 222
 non-pharmacologic management, 167
 risk factors in PD, 164
 pallidal DBS. *See* globus pallidus internus
 (GPi) DBS
 pallidothalamic tract, 219
 pallidotomy, 167, 187, 297. *See also* surgery
 bilateral, 302
 introduction, 175
 outcomes, 179–81, 182
 pain and, 162
 posteroventral, 297, 301, 302
 revitalization, 176
 target confirmation, 177
 unilateral, 300–301
 panic attacks, 130
 parallel group studies, 268
 paranoid delusions, 131
 pardoprunox, 284
 paresthesias, 211
 Parkinson, James, 1, 162
 Parkinson's Progression Markers Initiative
 (PPMI), 251
 Parkinson's disease. *See also* advanced stage
 PD; early stage PD
 atypical, 66, 196, 243, 281
 behavioral effects of treatment, 139–40,
 148
 benign tremulous, 213
 cholinergic system and, 5–6
 clinical diagnosis, 63
 experimental pharmacological
 treatment, 83–91
 first recognition, 1
 mid stage PD, 316–20
 pathological changes, 4
 stages, 3
 summary of treatments for advanced
 stage, 72–73
 summary of treatments for early stage, 72
 symptoms, 2–3
 UK Brain Bank Criteria, 281
 paroxetine, 133, 327
 passage hallucinations, 131
 patient-reported outcomes (PRO), 231,
 234–36
 PD Sleep Scale, 154
 PDQ-39, 84, 199, 237, 301, 307
 PDQ-8, 237
 PDQL scale, 237
 PDSS scale, 236
 PDSS-2 scale, 41, 236
 PDYS-26 scale, 235
 peak V02, 349
 pedal edema, 42
 pedunculopontine nucleus (PPN), 6,
 216–18, 218
 pelvic floor muscle exercises, 102
 Penetration-Aspiration scale, 340
 percutaneous endoscopic gastrostomy
 (PEG), 70
 pergolide, 35, 37, 104, 155
 periodic limb movement disorder (PLMD),
 152
 periodic limb movements of sleep (PLMS),
 156
 peripheral edema, 42
 peripheral neuropathy, 166, 168–69
 personality, 128
 PET scanning, 242, 243, 246, 250
 Fdpeta PET, 316
 FD-PET, 266
 REAL-PET study, 244, 250, 267, 272, 275
 PFS-16 scale, 236
 phencyclidine, 14
 physical exercise, 114, 117–18, 165, 167,
 349
 aerobic, 349–50
 dance, 355–56
 early stage PD, 285
 resistance training, 351–52
 Tai-Chi, 352–53
 physiological fatigue, 134
 pimavanserin, 132, 142, 329
 PIMS scale, 237
 pimavanserin, 331
 piribedil, 35, 36, 37, 41
 mechanism of action, 41
 motor systems efficacy, 41
 non-motor systems efficacy, 41
 transdermal patch, 52
 Pittsburgh Sleep Quality Index, 154
 placebo response, 330
 pneumonia, aspiration, 340
 polyethylene glycol (PEG) 3350, 99
 polysomnography, 154, 347

Index

- portable pumps, 54
posterior subthalamic area (PSA), 218–19
postural hypotension, 42, 105
posture, 289
PPMI study, 254, 255
pramipexole, 35, 36, 37–39, 133, 156
 adverse effects, 41
 depression, 328
 early stage PD, 283–84
 formulations, 283
 major trials, 272, 275
 mechanism of action, 37
 motor symptoms efficacy, 38–39
 non-motor symptoms efficacy, 39
 pharmacokinetics, 50
PRECEPT study, 90, 273, 276
preladenant, 87
presence hallucinations, 131
PRESTO trial, 25
primary pain, 164, 165
probiotics, 99
procyclidine, 7
prodromal syndrome, 280
PROGENI study, 280
progression biomarkers, 260
proteomics, 259
PROUD study, 272, 275
prucalopride, 98, 99
psychiatric complications, dopamine
 agonists, 34
psychosis, 131–32, 328–29
 dopamine agonists, 42
 drug treatment causing, 132
 induction, 17
 medications causing, 131
 symptoms, 328
 treatment-related, 140–42
PSYCLOPS study, 329
psyllium, 98
punding, 66, 142
purines, 256
pyridostigmine, 96, 100
- QE3 study, 273
Quality of Life (QoL), 55
 DBS and, 318
 GPI vs STN DBS, 291
 health-related scales, 236–37, 238
 PDQ-39, 84, 199
 unilateral pallidal DBS, 301
quetiapine, 132, 142, 329
QUIP-RS scale, 143, 235, 330
- radicular pain, 165, 166
radiofrequency thermolesion, 178
radiotherapy, 102
ramelteon, 156
rasagiline, 68
 adverse effects, 27
 clinical trials, 26, 272, 274
 cognitive impairment, 112, 113, 327
 depression, 328
 early stage PD, 285
 EFNS/MDS guidelines, 30
 levodopa adjunct therapy, 25–26
 MDS guidelines, 30
 selegiline comparisons, 27
 sleep disturbances, 156
Rasch measurement theory, 231
rating scales, 231–32, 249
 classification, 231
 clinician-based, 232–34
 development and validation, 231
 global severity and disability, 232
 global severity and multidomain, 238
 main psychometric attributes, 232
 motor complications and dyskinesias, 233
 motor impairment and disability, 233
 motor symptoms and disabilities, 235
 multidomain, 233
 non-motor symptoms, 234, 235–36, 238
 NPS clinical trials, 332
 patient-reported outcomes, 234–36
 quality of life, 236–37, 238
RDRS scale, 234
REAL-PET study, 244, 250, 267, 272, 275
RECOVER study, 40, 51
rectal laxatives, 99
REM sleep disorder, 128, 141, 152, 153, 347
 treatment, 156
repetitive transcranial magnetic
 stimulation (rTMS), 104, 118, 168
reproducibility, rating scales, 232
rescue therapy, 54, 55
resistance training, 351–52
responsiveness, in rating scales, 231, 233
rest tremor, 3, 208
restless legs syndrome (RLS), 152, 156,
 165, 166
restorative rehabilitation, 112, 113, 114
rigidity, 3
rivastigmine, 123, 124, 156
 apathy, 330
 cognitive impairment, 112, 113
 dementia, 325
 psychosis, 329
 sleep disorders, 347
ropinirole, 35, 36, 37, 39–40, 156
 early stage PD, 284
 major trials, 272, 275
 mechanism of action, 39
 motor systems efficacy, 39
 non-motor systems efficacy, 39
 pharmacokinetics, 50
rotigotine, 35, 36, 37, 40–41
 early stage PD, 284
 insomnia and, 155
 mechanism of action, 40
 motor systems efficacy, 40
 non-motor symptoms efficacy, 40
 pharmacokinetics, 50
rotigotine transdermal system (RTS), 49, 58
 impulse control disorders and, 52
 long-term effects, 51
 motor symptoms, 50
 non-motor symptoms, 51
 pharmacokinetics, 49–50
 side effects, 52
- safinamide, 88–89, 284
SAPS-PD scores, 329
schizophrenia, 131, 142
SCOPA-AUT scale, 236
SCOPA-Cog scale, 234
SCOPA-Motor, 233
SCOPA-PC scale, 234
SCOPA-PS, 237
SCOPA-Sleep scale, 154, 236
SEAPI scale, 343
secondary pain, 164, 165
seizures, 201
selegiline, 24, 68
 adverse effects, 27
 efficacy, 24
 EFNS/MDS guidelines, 30
 insomnia from, 153
 major trials, 271, 272, 274
 MDS guidelines, 30
 neuroprotective potential, 24–25
 orally disintegrating tablet, 27
 rasagiline comparisons, 27
SEND-PD scale, 236
senna, 99
serotonin receptors, 141
serotonin syndrome, 27–28
sertraline, 328
SES scale, 233
sexual dysfunction, 104–6. *See also*
 erectile dysfunction
 drugs contributing to, 104
SF-36 scale, 237
shopping, compulsive, 142
sialorrhea, 8, 100–102, 337–40
 drug treatment, 95
sildenafil, 105, 343
SINDEPAR study, 272, 274
single-domain MCI, 111, 122
SIP scale, 237
skin nodules, 57
sleep attacks, 153, 157
sleep disorders, 134, 151, 346–47.
 See also REM sleep disorder
 daytime, 41, 152–53, 345–46
 diagnosis, 153
 dopamine agonists, 41
 EDS, 152, 157, 345
 guidelines, 155
 management, 154–58
 nighttime, 151–52
 pathopathology, 153
 PPN DBS and, 218
 scales, 236
smoking, 128
social phobia, 130
solanezumab, 255
solifenacin, 103
somatostatin, 282
SPECT scanning, 242, 243, 250
speech impairments, 354
speech-language therapy, 337
spinal cord, degeneration, 163
SSRIs, 130, 133, 327, 328
Stalevo®, 78, 81
standard error of measurement (SEM),
 233
standardized response mean (SRM), 231
STEADY-PD study, 90

- stereotactic surgery, 167, 175, 177, 198, 292, 297. *See also* deep brain stimulation (DBS)
- stimulant laxatives, 99
- stimulants, 135
- stimulation related side effects, 201
- stool softeners, 99
- striatum, 5
- STRIDE-PD study, 65, 68, 79
- structural imaging, 243, 268
- subcutaneous apomorphine, 100
- subcutaneous dopamine agonists, 53–58
- substantia nigra (SNr), 219–21
- subthalamic nucleus (STN) DBS, 146, 147, 157, 287
- advantages, 195
 - adverse effects, 198, 199–202
 - anatomy and physiology, 288
 - background, 287
 - bilateral, 306–8
 - future uses, 202
 - vs. GPi DBS, 190, 192, 294
 - indications and patient selection, 195–96
 - introduction and history, 195
 - mechanism of action, 199
 - medication reduction, 291–92
 - motor symptoms, 289–90
 - neuroimaging, 292
 - non-motor symptoms, 290–91
 - operation risks, 293
 - outcomes and efficacy, 199
 - pain management, 344
 - PPN DBS and, 218
 - procedure, 198–99
 - programming challenges following, 292
 - stimulation, 288
 - timing of, 196
 - unilateral, 305–6
- subthalamotomy, 181–82, 183, 219. *See also* surgery
- bilateral, 306
 - unilateral, 304–5
- suicide, 147, 201, 318
- supine hypertension, 96, 97
- surface electrical stimulation therapy, 341
- surgery, 175, 297–98. *See also* deep brain stimulation (DBS); pallidotomy; stereotactic surgery; subthalamotomy; thalamotomy
- advantages and drawbacks, 298
 - vs. DBS controversy, 308–9
 - epidural spinal cord stimulation, 222–24
 - indications, 176
 - lesioning technique, 178
 - motor cortex stimulation, 222
 - non-invasive brain stimulation, 224
 - outcomes, 178–82
 - patient preparation, 177
 - patient selection, 176
 - safety and side effects, 182–83
 - target confirmation, 177–78
 - target planification, 177
- surrogate markers, 249, 260
- swallowing therapy, 340
- sweating, excessive, 106
- SWEDDs, 243, 266
- synuclein alpha, 253–54, 268
- tai-chi, 352–53
- tango dancing, 355, 356
- tau protein, 255, 268
- TCH346 study, 273, 276
- tegaserod, 98, 99, 341
- TEMPO study, 26, 30, 272, 274
- testosterone replacement therapy, 105
- thalamic DBS, 298–300
- thalamotomy, 206, 297. *See also* surgery
- introduction, 175
 - non-invasive, 308
 - outcomes, 178–79, 182
 - vs. thalamic DBS, 298–300
- thermolesion, 176, 178
- thermoregulatory dysfunction, 106
- tocopherol, 271, 272
- tolcapone, 67, 77, 79–80
- tolterodine, 102
- toxin-induced models, 271
- tozadenant, 87–88
- transcranial direct current stimulation (tDCS), 118
- transcranial ultrasound, 243
- transcriptomics, 258–59
- transdermal dopamine agonists, 48, 58
- apomorphine, 52
 - delivery routes, 49
 - lisuride, 52
 - piribedil, 52
 - rotigotine, 49–52
- transgenic models, 271
- TRAP pneumonic, 2
- treadmill/gait training, 350
- tremors
- anticholinergic effects, 8
 - benign tremulous parkinsonism, 213
 - GPi vs STN DBS, 289
 - rest tremor, 208
 - thalamotomy vs thalamic DBS, 299
 - VIM DBS treatment, 206, 208, 210
- tricyclic antidepressants, 103, 133, 327
- trihexyphenidyl, 5, 7, 101
- tropicamide, 101, 340
- trospium, 102
- Unified Dyskinesia Rating Scale, 89, 234
- unilateral GPi DBS, 301–2
- unilateral pallidotomy, 300–301
- unilateral subthalamic DBS, 305–6
- unilateral subthalamotomy, 304–5
- United Kingdom Brain Bank criteria, 281
- UPDRS scores, 24, 26, 67, 266, 269
- bilateral pallidal DBS, 303
 - bilateral pallidotomy, 302
 - bilateral STN DBS, 307
 - bilateral subthalamotomy, 306
 - GPi DBS, 189, 290
 - MDS-UPDRS, 266
 - pallidotomy, 300
 - resistance training, 351
 - STN DBS, 196, 199, 290
 - subscales, 233
 - unilateral pallidotomy, 300
 - unilateral STN DBS, 305
 - unilateral subthalamotomy, 305
 - VIM DBS, 209
- urate, 256
- urge incontinence, 102
- uric acid precursor, 90
- urinary dysfunction, 102–4, 342–43
- drug treatment, 95
- urinary incontinence, 343
- validity, rating scales, 232
- variability between laboratory measures, 260
- venlafaxine, 133, 327
- ventral intermediate nucleus (VIM) DBS, 206
- adverse effects, 211, 212
 - BTP treatment, 213
 - neuroanatomy, 206
 - neurophysiology, 207
 - procedure, 207
 - rebound effect, 211
 - stimulation parameters, 211
 - surgery results, 208–11
- verbal fluency, 317
- video-assisted swallowing therapy (VAST), 340
- visual analog scales (VAS), 340
- visual field defects, 301
- visual hallucinations, 131, 141
- visuospatial deficits, 111
- VitalStim®, 341
- vitamin B12 deficiency, 168
- vitamin D deficiency, 282
- VMAT2, 267
- washout period, 265, 268, 274
- wearing-off, 76, 80
- weight gain, 293
- weight loss, 342
- WINCS, 224
- WOQ scale, 235
- xanthine, 253
- XP 21279, 69, 85–86
- younger patients, treatments in early stage, 72
- zona incerta (Zi), 218, 219